Date of Thesis Acceptance
Major Department or Program
Proteases are enzymes that cleave peptide bonds. One such protease is the 20S proteasome, a ubiquitous complex with a threonine-containing active site. This barrel-shaped proteasome has three distinct binding activities, chymotrypsin-like, trypsin-like, and PGPH that are specific for certain substrates. Inhibition of these binding sites of the 20S proteasome confers one method of cancer therapy. This research explores the synthesis of macrocyclic bimodal inhibitors modeled after the natural product TMC-95A, which inhibits the proteasome by a hydrogen-bonding network. Our inhibitors additionally contain a functional group that reacts with the catalytic nucleophile of the enzyme. The synthetic strategy consists of preparation of a tripeptide by solid phase synthesis followed by N-terminal coupling of a non-natural phenylalanine analog, which is synthesized starting from a benzene derivative. The first of these inhibitors has been assessed via steady-state kinetics. The dissociation constant Ki was determined to be 1.6 nM for the chymotrypsin-like activity of the 20S rabbit proteasome, followed by 13 nM and 3.5 nM for the trypsin and PGPH activity, respectively. This compound successfully inhibits the proteasome, which is promising for the other inhibitors that have been synthesized but not yet evaluated.
Protease inhibitors, Bortezomib, peptidylglutamylpeptide hydrolase, Threonine, Synthesis -- TMC-95A, TMC-95A, Chemical inhibitors, Enzymes, Whitman College 2012 -- Dissertation collection -- Chemistry Department
Public Accessible Thesis
If you have questions about permitted uses of this content, please contact the ARMINDA administrator
In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).